CD80 and neoplasm: In the phase Ib/II PRINCE study of sotigalimab plus chemotherapy ± nivolumab in pancreatic adenocarcinoma, the total ORR was 58% in the phase Ib part,319 while in phase II part, the confirmed ORR of sotigalimab plus chemotherapy was 33%.319 Mitazalimab efficiently upregulated CD80/CD86 expression and IL-12 secretion by DCs, induced antigen-specific T cell proliferation and anti-tumor activity preclinically.320,321 Efficacy evaluation is ongoing in the phase II OPTIMIZE-1 study combining mitazalimab and chemotherapy in pancreatic ductal adenocarcinoma (PDAC) patients.